Article
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Leukemia & lymphoma - 1 Dec 2018
de Jong Jan, Hellemans Peter, De Wilde Severijn, Patricia Daniel, Masterson Tara, Manikhas Georgii, Myasnikov Alexander, Osmanov Dzhelil, Córdoba Raúl, Panizo Carlos, de Zwart Loeckie, Snoeys Jan, Chauhan Vijay, Jiao James, Sukbuntherng Juthamas, Ouellet Daniele
Abstract excerpt
This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations. During cycle 1, patients received oral ibrutinib 560 mg qd alone (Days 1-4 and 14-18), and ibrutinib 140 mg (Days 5-13; 19-27) plus erythromycin 500 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.